The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner...

The NIHR Biomedical Research Centre for Mental Health London has Joined the
MetaMiner CNS Partnership Program

ST. JOSEPH, Mich., March 24 /PRNewswire/ -- GeneGo, Inc., the leading systems
biology tools company, announced today that the NIHR Biomedical Research
Centre for Mental Health at the South London and Maudsley NHS Foundation Trust
and King's College London (BRC-MH), has joined the MetaMiner CNS Partnership
Program. Professor Simon Lovestone, Centre Director, and Dr. Gerome Breen are
leading the BRC-MH team for this project. The goal of the program is to
develop a proprietary Central Nervous System (CNS) pathway analysis platform
built by experts in the field. This includes developing a series of blueprint
CNS disease pathway maps for Schizophrenia, Alzheimer's disease and
Huntington's disease, etc. as well as collecting experimental data from the
public domain, and making it available for analysis.

Professor Lovestone said: "This is an important initiative as it will give
researchers a global perspective of CNS pathways and enable those new to the
field to get up to speed quickly. Currently there is a huge amount of CNS
data available but until now no one has brought it all together in a
comprehensive form."

Dr. Breen, BRC-MH Genetics Coordinator, adds, "Accurate and comprehensive
pathway annotation is necessary for us to discern the biological mechanisms
revealed by large scale omics approaches to CNS disorders, such as genomewide
association and expression array studies."

Julie Bryant, GeneGo's VP of Business Development, comments, "The BRC-MH at
KCL has world class expertise in CNS disorders and we are pleased to have the
Centre on our team. We plan to develop excellent and accurately annotated CNS
pathway maps, while fully processing experimental data taken from public
repositories such as GEO. This will ultimately mean superior CNS pathway
annotation and facilitate easier data analysis and exploration for our
customers."

About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based
pathway analysis, cheminformatics & bioinformatics software for life science
research. The original computational MetaDiscovery(TM) platform allows an
integration and expert analysis of different kinds of experimental data (mRNA
expression, proteomics, metabolomics, microRNA and other data) and relevant
bioactive chemistry (metabolites, drugs, other xenobiotics) within the
framework of curated biological pathways and networks. GeneGo's flagship
product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of
target selection and validation, data mining in biology, identification of
biomarkers for disease states and toxicology. The second product, MetaDrug
5.2(TM) is designed for prediction of human metabolism, toxicity and
biological effects for novel small molecules compounds. MetaBase(TM)
represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

National Institute for Health Research (NIHR) Biomedical Research Centre (BRC)
for Mental Health
The BRC for Mental Health at the South London and Maudsley NHS Foundation
Trust and the Institute of Psychiatry, King's College London is one of 12
national biomedical research centres created through the partnership of a
leading National Health Service (NHS) provider and an outstanding university.
The Centres are funded by the UK's Department of Health through the National
Institute for Health Research (NIHR). The BRC for Mental Health was selected
through open competition by an international expert selection panel and as
such is distinguished as a leader in scientific translation. Its purpose is to
accelerate the translation of fundamental biomedical research into clinical
practice for patient benefit. One way it will achieve this is through the
early adoption of new insights in technologies, techniques and treatments for
health improvement. It is the only biomedical research centre specializing in
mental health in the UK. For further information visit www.iop.kcl.ac.uk.

South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust provides the most extensive
portfolio of mental health services in the UK, supported by internationally
recognised training and research. The Trust is increasingly focussed on
promoting mental health and well-being rather than simply responding to severe
mental illness. The provision of integrated adult services enables the Trust
to address both people's mental health and social care needs. In particular
the Trust is focussing on early intervention, getting help to people sooner in
the course of illnesses such as psychosis and dementia, and in supporting
people with mental health problems at an earlier stage of their lives,
especially young people. For further info www.slam.nhs.uk.

King's College London
King's College London is one of the top 25 universities in the world (Times
Higher Education 2008) and the fourth oldest in England. A research-led
university based in the heart of London, King's has 19,700 students from more
than 150 countries, and 5,400 employees. King's has an outstanding reputation
for providing world-class teaching and cutting-edge research. In the 2008
Research Assessment Exercise for British universities, 60 per cent of research
activity at King's was deemed world-leading or internationally excellent. The
College is in the top group of UK universities for research earnings and has
an overall annual income of approximately 450 million pounds Sterling. An
investment of 500 million pounds has been made in the redevelopment of its
estate.

SOURCE GeneGo, Inc.

Julie Bryant, VP Business Development and Marketing of GeneGo, Inc.,
+1-858-756-7996, julie@genego.com